Spyre spies another edge for UC ambitions with midstage win for anti-TL1A antibody
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients’ Robart’s Histopathology Index (RHI) scores by week 12.
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients’ Robart’s Histopathology Index (RHI) scores by week 12.